Sutro Biopharma (STRO) Up 50% on Cancer Treatment Collaboration

Business and Finance

Shares of Sutro Biopharma STRO rallied 50.6% after-hours on Jun 27 after it announced a strategic partnership and licensing agreement with Japan’s pharma giant Astellas Pharma. Per the deal, the companies will develop novel immunostimulatory antibody-drug conjugates (iADCs) for cancer.Sutro will leverage its own original iADC technologies to make iADCs for three distinct biological targets. iADCs are a next-generation modality with unique cancer-fighting potential for the treatment of cold tumors. iADCs have the potential to offer new options for patients who have not responded well to existing immune checkpoint inhibitors.iADCs are targeted medicines delivering chemotherapy agents to cancer cells. An iADC, combines a monoclonal antibody with a linker through which it delivers the chemo agent to the ...

Yahoo     Jun 28, 2022